Objective of the study: To evaluate the efficacy of LSG on glucose homeostasis in morbidly obese subjects with Type 2 Diabetes Mellitus (T2DM) and to elucidate the role of disease duration on resolution.
Methods: From October 2002 to August 2009, 240 patients underwent LSG for morbid obesity. Fifty-eight patients presented T2DM: 15 of them had a diabetes duration >10 years (F/M 9/6, mean age 52.2±5.3, mean pre-operative BMI 44.9±6.7 Kg/m2): GROUP A; 43 patients had a diabetes duration <10 years (F/M 35/8, mean age 49.7±7, mean pre-operative BMI 46.9±11.7 Kg/m2): GROUP B.
Results: In GROUP A 11 patients were on oral hypoglycaemic agents and 4 on insulin therapy. In GROUP B 38 patients were treated with oral hypoglycaemic and 5 on insulin therapy.
At 3 months after LSG 49/58 patients (84.5%) discontinued the antidiabetic therapy. The 3 months post-operative data for each group are reported in table:
| Follow-up: 3 months | BMI (Kg/m2) | Fasting Glycaemia (mg/dl) | Cured patients (%) | ||
| Pre-op | Post-op | Pre-op | Post-op | ||
| GROUP A (n=15) | 44.9±6.7 | 36.1±4.2 | 237.4±56.4 | 101.5±18.3 | 6 (40) |
| GROUP B (n=43) | 46.9±11.7 | 37.6±6.7 | 132.9±30.7 | 95.2±22 | 43 (100) |
However, in the “non cured” group the patients were more sensitive to lower doses of antidiabetic drugs. Significantly reduced dosages were able to obtain normal fasting glycaemia levels.
Conclusions: The LSG is effective in the treatment of obese patients with T2DM. Diabetes duration seem to be paramount prognostic factor, being 10 years a cut-off between a 100% cure and a less percentage of resolution.
Session: Poster
Program Number: P061
